Preliminaray Studies on Anti-glioma Effect of Temozolomide Delayed-Release Microspheres in Subcutaneous Xenograft Model

WU Zi-cheng,DONG Jun,XIANG Zhao-hui,ZHOU Guang-hua,HUANG Qiang,LAN Qing,WU Xin-yong

2010-01-01

Abstract:Objective To observe the anti-glioma effect of temozolomide delayed release microspheres P-TMZ in SHG-44 subcutaneous xenograft model. Methods The SHG-44 glioma cells( 1 × 107) were inoculated subcutaneously into the right axil of Balb/c nude mice. The tumor was resected and cut into pieces,and inoculated subcutaneously ( 2 mm3 /mouse) . When xenograft tumor size reached about 65mm3,tumor-bearing mice were divided randomly into the 6 groups ( 10 mice/group) ,namely P-TMZ group,TMZ group,P-TMZ plus TMZ group ,BCNU group,the non-loaded microspheres ( P-0) group and normal saline ( NS) group. P-TMZ( 500 mg/kg) ,and P-0( 500 mg/kg) were suspended with DMEM to the final volume of 150μl and injected slowly into the tumors. TMZ( 50 mg/kg) was administered with gavage everyday for 5 days. BCNU( 40 mg/kg) was injected into the tail vein once,NS was injected directly ( 150 μl/mouse) into tumor tissues. Tumor size was measured every 4 days till 28 days after treatment. Results Tumor inhibition ratios of P-TMZ,P-TMZ plus TMZ ,and BCNU were significantly higer than P-0 and NS( P < 0. 01) ; P-TMZ,P-TMZ plus TMZ and BCNU were more effective than TMZ ( P < 0. 05) . TMZ showed definite anti-tumor effect when compared with P-0,NS ( P < 0. 05) . Conclusion P-TMZ retaines anti-tumor activity of TMZ and has better therapeutic effect against glioma when administered locally.